Divi's Laboratories shares climb over 10% in 2 sessions: Should you buy, sell or hold?

Shares of Divi's Laboratories extended their erstwhile day's gains and gained up to 5.36 per cent at the day's precocious successful Tuesday's league to Rs 6,205 per stock connected the BSE. In 2 sessions station the company's Q3 earnings, the banal has climbed arsenic overmuch arsenic 10.37 per cent.

For the December 4th of the FY25, pharma large Divi's Laboratories reported a 64 per cent year-on-year (YoY) leap successful consolidated nett net to Rs 589 crore, up from Rs 358 crore successful the aforesaid play past year.

Revenue from operations during the reappraisal play besides surged 25 per cent on-year to Rs 2,319 crore successful examination to Rs 1,855 crore successful the corresponding play of the erstwhile year.

The institution has commenced commercialized operations from a portion of the Phase 1 of Unit III greenfield task astatine Ontimamidi Village, adjacent Kakinada, Andhra Pradesh from January 01, 2025.

Should you buy, clasp oregon merchantability Divi's Laboratories shares?

Global brokerages largely remain divided on Divi's Laboratories banal outlook aft its Q3 earnings. Goldman Sachs maintains a 'neutral' telephone connected the antagonistic with the people raised to Rs 5,925 from Rs 5,665 per share. The brokerage foresees scope for marketplace stock gains successful molecules for Divi's wherever planetary stock is 25-30 per cent.

Also, the comnpany is seeing a ramp-up following ongoing investments successful peptides, sartans, and opposition media.

Furthermore, the brokerage reiterated double-digit maturation outlook for the largecap pharma large and increased FY25-28 EPS estimates by 8 per cent. 

Meanwhile, different overseas brokerage HSBC has continued with its 'reduce' standing connected the stock, pegging the people astatine Rs 5,425, implying imaginable downside of astir 8 per cent.